Loading Events

« All Events

2nd Annual European HealthTech CEO Forum

March 8 - March 9

€1700

Due to the pandemic, Sachs Zurich events will be hosted in a digital format for the first time. This will allow us to further support our community and past attendees. We will provide both the usual stimulating program and networking opportunities through our online video and audio meeting system.The main programme for the 2nd Annual EHTF is spread throughout 2 days (8th-9th of March) and will include HealthTech Innovation Day, focusing on Investment & Partnership in MedTech and Digital Health, and Pandemic Response Day, focusing on new developments in tackling pandemic. The programme will feature topical keynotes and panels with industry leaders as well as over 20 corporate presentations by public, private and growth companies, plus over 20 pitches by seed companies. We anticipate 300+ delegates, including major and growth corporates, financial investors/partners, bankers and advisors.Meetings will take place from the 8th to 12th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. ​The conference will be held in the Central European Time Zone. The digital event will consist of:HealthTech Innovation Day (Monday, 8th of March)

  • Digital Healthcare in the New Era of COVID-19 Panel
  • Digital Pharma & Drug Discovery Panel
  • MedTech & Device BD and Investment Panel
  • Revolutionising Hospital Care: New Technologies Panel
  • Innovation in Care Technology Panel
  • Innovation & Early Stage Investment Roundtable

Pandemic Response Day (Tuesday, 9th of March)

  • The Global Supply Chain in the Time of COVID-19 Panel
  • Overview of Vaccine Development & Roll Out Panel
  • Advanced Therapeutics Panel
  • Diagnostics: New Technologies Panel
  • Patient Care in the Time of the Pandemic Panel

Networking Days (10th – 12th of March)Confirmed Keynote Speakers Include:

  • Introductory Speech by Jeffrey Cohen, Managing Director, Equity Research, Ladenburg Thalmann & Co. Inc.
  • Mark Stevenson, Executive Vice President & Chief Operating Officer, Thermo Fisher Scientific
  • Keynote Speech by Sean Marett, Chief Business Officer & Chief Commercial Officer, BioNTech SE

Confirmed Speakers Include:

  • Alex Zhavoronkov, Founder & CEO, Insilico Medicine, Inc.
  • Alexandra Vallon-Eberhard, Sr. Director Global BD
  • Amir Jafri, Founder & CEO, Immunicom, Inc.*
  • Amit Nastik, Head of Strategy & Operations & Local Market Manufacturing, Novartis International AG
  • André Heeg, Managing Director & Partner, BCG Digital Ventures
  • Beat Merz, Managing Director, New Harbor Venture Partners, LLC
  • Christoph Pedain, Head of Point of Care, Siemens Healthineers AG
  • Daniel O’Mahony, Partner, Seroba Life Sciences
  • Daniel Vitt, CEO, Immunic Therapeutics
  • David Cole, Head of Business Development & Innovation, IBM Watson Health
  • David Gordon, Head of Investments, Longliv Ventures
  • Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
  • Elena Bonfiglioli, Managing Director Health and Life Sciences, EMEA, Microsoft Corporation
  • Erich Tauber, CEO, Themis Bioscience GmbH (wholly-owned subsidiary of Merck & Co., Inc.)
  • Eyal Zimlichman, Deputy Director General, CMO and CIO, Sheba Medical Center
  • Florian Schödel, Owner, Philimmune, LLC
  • Guy Goldberg, CBO, RedHill Biopharma Ltd.
  • Heather Roxborough, Partner, Optum Ventures
  • Itschak Friedman, Venture Partner, LionBird (Ventures) Ltd.
  • Jan Lichtenberg, CEO, InSphero AG
  • Jeremy Sohn, VP, Global Head of Digital Business Development & Licensing, Novartis International AG
  • Johan Van Hoof, Global Therapeutic Area Head of Infectious Diseases & Vaccines and Managing Director, Janssen Vaccines & Prevention B.V.
  • Jonathan Goldstein, Director, Corporate Research & Ventures, Boston Scientific
  • Kate Broderick, Senior Vice President, R&D, INOVIO Pharmaceuticals, Inc.
  • Klaus Stoeckemann, Co-Founder and Managing Partner, Peppermint VenturePartners GmbH
  • Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
  • Lionel Carnot, Partner, Earlybird Venture Capital
  • Lior Shahory, General Partner, Peregrine Ventures
  • Lloyd Diamond, President & CEO, Pixium Vision SA
  • Lorenzo Positano, Partner & Managing Director, Boston Consulting Group
  • Mark Andrews, Managing Director, PharmaVentures Ltd.
  • Martin Pfister, Principal, High-Tech Gründerfonds Management GmbH
  • Martin Potgeter, Vice President, Corporate Business Development, QIAGEN GmbH
  • Martin Rothman, Venture Partner, Sofinnova Partners
  • Martin-Immanuel Bittner, Co-Founder & CEO, Arctoris Ltd.
  • Max Herrmann, Managing Director, Stifel Financial Corp.
  • Narender Mantena, Head, Global Strategy & CEO, Specialty Generic Injectables & Synthetic Biology, Biological E Ltd.
  • Patrick Griss, Executive Partner, Zühlke Ventures AG
  • Patrik Sobocki, Venture Investor, Industrifonden
  • Peter Llewellyn-Davies, CEO & CFO, APEIRON Biologics AG
  • Philippe Pouletty, Co-Founder & Managing Director, Truffle Capital
  • Prashant Yadav, Senior Fellow, Center for Global Development (CGD)
  • Raghuram Selvaraju, Chairman of the Board, Relief Therapeutics Holding AG and Managing Director, H.C. Wainwright & Co., LLC
  • Rainer Metzger, Head of Integrated Clinical Services, Medicover AB
  • Rao Movva, Novartis Distinguished Scientist & Independent Pharma & Biotech Advisor, Independent – RM
  • Regina Hodits, Managing Partner, Wellington Partners
  • Richard Marsden, CEO, Synairgen Research Ltd.
  • Samuel Levy, Founding Partner, Lauxera Capital Partners
  • Ségolène Perin, Director of Innovation, ELSAN
  • Shai Novik, Executive Chairman, Enlivex Therapeutics, Ltd.
  • Stefano Cazzaniga, Partner and Director, Health Care Payers & Providers, Boston Consulting Group
  • Tamir Meiri, Senior Manager, Venture Investments, Johnson & Johnson Innovation
  • Thijs Cohen Tervaert, Junior Partner, INKEF Capital BV
  • Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC
  • Timothy Herpin, VP, Business Development, Infectious Diseases and Vaccines, Johnson & Johnson Innovation | Janssen Business Development
  • Tryggvi Thorgeirsson, Co-Founder & CEO, SidekickHealth
  • More TBA…

Details

Start:
March 8
End:
March 9
Cost:
€1700
Event Category:
Website:
https://www.sachsforum.com/2ehtf-about.html

Organizer

Sachs Associates Ltd
Phone:
+44 203 463 4890
Email:
SachsTeam@SachsForum.com